New Delhi, April 2 -- In a first, India plans to publicly disclose findings from inspections of drug manufacturing units, marking a shift towards greater transparency and quality monitoring, according to two government officials and documents reviewed by Mint.

According to the proposal being discussed, the country's apex drugs regulator, Central Drugs Standard Control Organization (CDSCO), will publish details of inspected firms and audit recommendations on its website, as India's pharmaceuticals sector faces heightened scrutiny over quality.

The plan assumes significance for the country's $50 billion pharmaceutical market in the backdrop of Indian-manufactured cough syrups being linked to over 140 deaths in countries, including Gambia,...